Enterprise Value

16.8B

Cash

3.523B

Avg Qtr Burn

-434.4M

Short % of Float

2.86%

Insider Ownership

19.64%

Institutional Own.

50.09%

Qtr Updated

06/30/23


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date
BRUKINSA (zanubrutinib) Details
Blood cancer, Cancer, Small lymphocytic lymphoma , Chronic lymphocytic leukemia

Approved

Quarterly sales

TEVIMBRA Details
Cancer, Esophageal Squamous Cell Carcinoma

PDUFA

Approval decision

BRUKINSA + obinutuzumab Details
Cancer, Follicular lymphoma

PDUFA

Approval decision

Tislelizumab+ fluoropyrimidine + platinum chemotherapy Details
Cancer, Gastroesophageal junction tumors, Gastroesophageal adenocarcinomas

BLA

Submission

BRUKINSA + tislelizumab Details
Cancer, Hepatocellular carcinoma

Phase 3

Data readout

Tislelizumab Details
Cancer, Non-small cell lung carcinoma

Phase 3

Data readout

Ociperlimab (Anti-TIGIT) Details
Non-small cell lung carcinoma, Cancer

Phase 3

Data readout

BGB-11417 (Bcl-2 inhibitor) Details
Waldenstrom macroglobulinemia, Chronic lymphocytic leukemia

Phase 3

Initiation

Ociperlimab (anti-TIGIT Ab) + tislelizumab Details
Non-small cell lung carcinoma, Small cell lung cancer, Cervical cancer, Esophageal Squamous Cell Carcinoma

Phase 2

Data readout

BGB-16673 (BTK CDAC) Details
Cancer, B-cell malignancies

Phase 1

Data readout

BGB-A445 w/ tislelizumab Details
Renal cell carcinoma, Cancer, Bladder cancer, Melanoma

Phase 1

Update